0914 GMT - Sanofi's revised hospital drug-discount program in the U.S. holds long-term promise, although industry-wide implementation hurdles persist, Bryan Garnier Health analysts say in a note. The U.S. federal program, known as 340B and aimed at vulnerable patients, is increasingly used by hospitals to profit by charging the drugs' list prices while purchasing them at a discount, the analysts say. Under its new plan, Sanofi requires institutions to provide medical claims information before receiving discounts. Eli Lilly and Johnson & Johnson this month sued the federal government for rejecting similar rebate proposals. Sanofi reported in 2023 that discounts under Medicare and 340B led to a 15.7% decrease in its portfolio net price. Shares fall 0.3% to 92.89 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
November 25, 2024 04:15 ET (09:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。